Since OCT1 has the ability to transport derivatives of cisplatin, as well as paclitaxel12, 36, it is possible that ovarian cancer patients expressing reduced levels of OCT1 are associated with poor outcome following chemotherapy. This evidence concerns the gene SLC22A1 and ovarian carcinoma.